Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in thymic myoid cells | 0.75 |
| chemistry Open Targets | compounds already reach it: plitidepsin | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 7 Parkinson's papers of 297 | 0.73 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3674
Sealed predictions
- EEF1A2 in dopamine neurons, braak-0.57 (p 0.109) → -0.57 (p 0.108)receipt 3681
Swarm cases
receipt 3681: EEF1A2 in dopamine neurons, braak
- power
- full sample -0.47 (p 0.051, n 18), 95% CI -0.77 to +0.00. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.56 (p 0.017, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.74 (p 4.4e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.40, sign flips 0; without severely affected donors -0.47 (p 0.051, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EEF1A2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts